Spectrum says highest dose of ozarelix shows benefits in prostate cancer

By Elaine Rigoli

Tampa, Fla., Aug. 2 - Spectrum Pharmaceuticals, Inc. said data from its phase 2 trial with ozarelix for patients suffering from hormone-dependent prostate cancer showed that patients receiving doses of 130 mg per cycle of ozarelix showed the greatest continuous suppression of testosterone, the primary endpoint, where patients remained suppressed to castration until at least day 85.

In patients with continuous testosterone suppression, tumor response as measured by prostate-specific antigen levels was 97%, the company said in a news release.

Ozarelix was administered intramuscularly in 65, 100 or 130 mg doses according to different dosing schedules and repeated for three cycles of 28 days. The total dose by patient during the study ranged from 230 mg to 390 mg.

Ozarelix was well-tolerated at all dosages, the release said.

Spectrum Pharmaceuticals is a pharmaceutical company based in Irvine, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.